Friday, July 4, 2025 7/4/2025

TARGETING DRUG DELIVERY NANOPARTICLES TO SITES OF INFLAMMATION

Award Number: R42EY017518
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2006
PERIOD OF PERFORMANCE END DATE: 06/30/2012

Group Awards By:

View Award Description

TARGETING DRUG DELIVERY NANOPARTICLES TO SITES OF INFLAMMATION - DESCRIPTION (provided by applicant): The purpose of this Phase II STTR project is to develop a nanoparticle-based drug delivery system for use in the treatment of dry age-related macular degeneration (AMD). AMD is the leading cause of blindness for individuals over fifty-five years of age that live in the industrialized world, affecting approximately 10 million people in the US and as many as 30 million worldwide. There are two forms of the disease, both of which cause a loss of central vision. Approximately fifteen percent have wet, or exudative, AMD, which causes rapid, disabling blindness. The remaining eighty-five percent of patients have dry AMD, a less severe form that produces gradual vision loss. At present, there are no approved pharmacological agents approved for the treatment of dry AMD. This project seeks study to develop a "smart" poly-lactic, glycolic acid (PLGA) nanoparticle drug delivery system that can home to sites of inflammation after intravenous injection. Homing is achieved through a mechanism similar to one used by lymphocytes recognize regions of inflammation. Once there, the particles will release a complement inhibitor over a sustained period time. A growing body of research links excessive complement activation with several diseases of aging, including AMD. The prototype nanoparticle developed in Phase I is able to selectively bind activated endothelial cells in cell culture. In vivo studies further show that the nanoparticles are able to bind inflamed blood vessels in the eye. In vitro studies showed that they are also able to release a complement inhibitor for periods in excess of 60 days. PUBLIC HEALTH RELEVANCE This application is critically concerned with developing a drug product that can be used to treat nonexudative age-related macular degeneration. There are currently no approved treatments for this disorder, making it a major the issue of public health. In the longer term, the goal of this work is to develop drug products that can selectively target and treat sites of disease action, particularly those associated inflammation and degenerative disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2011 ( Subtotal = $0 )
2011	2009	KENTUCKY PHARMACEUTICALS	201 EAST JEFFERSON STREET	LOUISVILLE	KY	40202	JEFFERSON	USA	Vision Research	000	4	6/30/2011	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
														Subtotal = $0

Issue Date FY: 2010 ( Subtotal = $0 )
2010	2009	POTENTIA PHARMACEUTICALS	1434 GODDARD AVE	LOUISVILLE	KY	40204	JEFFERSON	USA	Vision Research	000	3	4/19/2010	NON-COMPETING CONTINUATION	-$391,672
2010	2009	KENTUCKY PHARMACEUTICALS	201 EAST JEFFERSON STREET	LOUISVILLE	KY	40202	JEFFERSON	USA	Vision Research	001	4	4/19/2010	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$391,672
														Subtotal = $0

Issue Date FY: 2009 ( Subtotal = $689,667 )
2009	2009	POTENTIA PHARMACEUTICALS	1434 GODDARD AVE	LOUISVILLE	KY	40204	JEFFERSON	USA	Vision Research	000	3	7/10/2009	NON-COMPETING CONTINUATION	$689,667
														Subtotal = $689,667

Issue Date FY: 2008 ( Subtotal = $287,662 )
2008	2008	POTENTIA PHARMACEUTICALS	1434 GODDARD AVENUE	LOUISVILLE	KY	40204	JEFFERSON	USA	Vision Research	000	2	9/8/2008	COMPETING CONTINUATION	$287,662
														Subtotal = $287,662

Grand Total All Awards = $977,329

Top

All Categories

About

Search

Reports

Data Submission

Award Information

TARGETING DRUG DELIVERY NANOPARTICLES TO SITES OF INFLAMMATION

Award Number: R42EY017518

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2006

PERIOD OF PERFORMANCE END DATE: 06/30/2012

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer